- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | RADIOPHARM THERANOSTICS LIMITED: Notification regarding unquoted securities - RAD | - | ASX | ||
| Do | RADIOPHARM THERANOSTICS LIMITED: RADOC New Class Options Range of Units and Top 20 Holders | 1 | ASX | ||
| Do | RADIOPHARM THERANOSTICS LIMITED: Application for quotation of securities - RAD | 1 | ASX | ||
| Do | RADIOPHARM THERANOSTICS LIMITED: Application for quotation of securities - RAD | 1 | ASX | ||
| Do | RADIOPHARM THERANOSTICS LIMITED: Share purchase plan completed | 3 | ASX | ||
| Mo | Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting | 1 | GlobeNewswire (USA) | ||
| Mo | RADIOPHARM THERANOSTICS LIMITED: RAD oral presentation at SNO26 on RAD101 Phase IIb data | - | ASX | ||
| 11.09. | RADIOPHARM THERANOSTICS LIMITED: Results of Meeting | 2 | ASX | ||
| RADIOPHARM THERANOSTICS Aktie jetzt für 0€ handeln | |||||
| 09.09. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 09.09. | Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma | 201 | GlobeNewswire (Europe) | Positive safety and favourable biodistribution seen in all subjects dosed Imaging data in all evaluable pancreatic cancer patients demonstrated significant tumor uptake Data support the... ► Artikel lesen | |
| 09.09. | RADIOPHARM THERANOSTICS LIMITED: RAD Announces Positive Data from RAD301 P1 Imaging Trial | 1 | ASX | ||
| 28.08. | RADIOPHARM THERANOSTICS LIMITED: Appendix 4E and Preliminary Final Report | - | ASX | ||
| 27.08. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 27.08. | RADIOPHARM THERANOSTICS LIMITED: Change of Director's Interest Notices x 4 | - | ASX | ||
| 26.08. | Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors | 223 | GlobeNewswire (Europe) | SYDNEY, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative... ► Artikel lesen | |
| 26.08. | RADIOPHARM THERANOSTICS LIMITED: RAD Doses First Patient in Second Cohort of BetaBart (RV-01) | - | ASX | ||
| 24.08. | RADIOPHARM THERANOSTICS LIMITED: Ceasing to be a substantial holder | 1 | ASX | ||
| 20.08. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 20.08. | Radiopharm advances RAD202 trial to higher dose level | 2 | Investing.com | ||
| 20.08. | Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial | 246 | GlobeNewswire (Europe) | Advancing RAD202 Phase 1 trial to next dose level of 180mCi in patients with HER2+ advanced solid tumors Previous diagnostic study of RAD202 in ten HER2-positive breast cancer patients demonstrated... ► Artikel lesen |
1 2 3 4 5 Weiter >>
98 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,863 | +0,63 % | Valneva-Aktie im Check am 18.09. (08:01 Uhr): Meine aktuelle Lageeinschätzung | ||
| PALATIN TECHNOLOGIES | 10,900 | +4,51 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| OCUGEN | 0,927 | +3,81 % | Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | The single global Phase 3 trial, ArMaDa3 (NCT07770828), is the first pivotal gene therapy trial in geographic atrophy (GA)U.S. Food and Drug Administration (FDA) granted OCU410 Regenerative Medicine... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,095 | -2,23 % | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026 | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026
Halle (Saale) / Munich, Germany, August 18, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 17,280 | -4,00 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,209 | +0,21 % | PacBio Appoints Mark Van Oene as President and Chief Executive Officer | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions,... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,568 | -4,12 % | RedHill Biopharma Ltd.: RedHill Divests Talicia to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities | Executes a major step in RedHill's strategic roadmap to fundamentally reposition the Company's commercial business toward new and larger product opportunities, revenue growth and an accelerated... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 8,750 | -1,13 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| VERASTEM | 6,510 | -0,97 % | Verastem Oncology stellt auf Konferenz zweigleisige RAS-Strategie vor | ||
| OXFORD NANOPORE TECHNOLOGIES | 2,038 | +1,95 % | Oxford Nanopore Wins Preliminary Injunction Against MGI Tech Over Cyclone Sequencing Systems | ||
| ROCKET PHARMACEUTICALS | 2,940 | -3,61 % | Rocket Pharma upgraded at Needham as FDA OKs pivotal trial design | ||
| VOYAGER THERAPEUTICS | 2,664 | +0,91 % | Voyager Therapeutics, Inc.: Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026 | - Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging... ► Artikel lesen | |
| PALISADE BIO | 1,595 | -6,18 % | Palisade Bio stellt Pläne für CED-Medikament auf Investorenkonferenz vor | ||
| XBIOTECH | 1,842 | +6,97 % | XBiotech Inc.: XBiotech startet klinische Phase-II-Studie zur Bewertung von Vilamakitug bei der Behandlung der aktiven axialen Spondyloarthritis | Der IND-Antrag für die V-SPINE-Studie hat die 30-tägige FDA-Prüfung ohne klinischen Stopp durchlaufen und ebnet damit den Weg für die Aufnahme von Patienten in den USAAUSTIN, Texas, June 15, 2026 (GLOBE... ► Artikel lesen | |
| PERSONALIS | 14,235 | +1,14 % | XFRA 04X: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen |
Das Unternehmen RADIOPHARM THERANOSTICS LIMITED ADR kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,650 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RADIOPHARM THERANOSTICS LIMITED ADR finden Sie auf Wallstreet Online.